What type of study is this?

December 8, 2025BloodOpen Access

High incidence of impaired graft function after allogeneic HSCT for myelofibrosis, and successful utilization of stem cell boost

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis finds 16% primary graft failure in myelofibrosis patients post-HSCT, suggesting stem cell boost could improve survival rates.

The 2-year overall survival rate was 40% for patients with primary graft failure and 75% for those with prolonged poor graft function.
Univariate analysis identified a DIPSS score greater than 3 and PTCy-based GVHD prophylaxis as significant predictors of impaired graft function.
Peripheral blood stem cells were the graft source in 90% of cases, while 76% received reduced intensity conditioning regimens.
These findings may highlight the need for earlier consideration of stem cell boost and optimization of GVHD prophylaxis in myelofibrosis treatment.

Philips et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis finds 16% primary graft failure in myelofibrosis patients post-HSCT, suggesting stem cell boost could improve survival rates.